Literature DB >> 2786762

Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera.

B Hofmann1, E Langhoff, B O Lindhardt, N Odum, J J Hyldig-Nielsen, L P Ryder, P Platz, B K Jakobsen, K Bendtzen, N Jacobsen.   

Abstract

Retroviral infections are accompanied by immunosuppression in a variety of species. For feline leukemia virus, the immunosuppression has been ascribed to the transmembrane envelope protein, p15E, which suppresses the proliferative responses of cat, mouse, and human lymphocytes. A similar suppressive effect has been shown for a lysate of human immunodeficiency virus (HIV), strain HTLV-IIIB. Here we determined that detergent-disrupted HTLV-IIIB lystate exerted a strong suppressive effect on PHA-stimulated lymphocytes. Preparations of whole virions, a lysate of a local HIV isolate grown on MP-6 cells, and a commercially obtained UV and psoralene-inactivated lysate were examined and demonstrated to have a similar suppressive effect. The HIV lysate was not directly cytotoxic to lymphocytes and did not contain tumor necrosis factor or lymphotoxin. The HIV lysate specifically suppressed the proliferation of a range of hemopoietic cell lines from man and mouse including three EBV transformed CD4- and IL-2 receptor-negative B-cell lines. The lysate also suppressed the formation of human bone marrow colonies, whereas the lysate had only a slight or no effect on fibroblasts. The suppression of lymphocyte proliferation was not abrogated by addition of IL-2 or IL-1 and the HIV lysate inhibited the expression of IL-2 receptors on suboptimal PHA-stimulated mononuclear cells. The suppressive factor(s) has not been characterized in molecular terms, but suppressive activity was recovered in fractions with a molecular weight of about 67,000 and in both the glycoprotein fraction and in the glycoprotein-depleted fraction of the HIV lysate. Sera from one-third of a small series (N = 13) of individuals with antibodies to HIV seem to be able to neutralize the suppressive properties of HIV lysate in cultures.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786762     DOI: 10.1016/0008-8749(89)90032-4

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes.

Authors:  B Hofmann; P Nishanian; T Nguyen; P Insixiengmay; J L Fahey
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

2.  Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Authors:  L E Brown; D O White; C Agius; B E Kemp; N Yatzakis; P Poumbourios; D A McPhee; D C Jackson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

3.  Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo.

Authors:  Wendy Fitzgerald; Andrew W Sylwester; Jean-Charles Grivel; Jeffrey D Lifson; Leonid B Margolis
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells.

Authors:  A Ammar; C Cibert; A M Bertoli; V Tsilivakos; C Jasmin; V Georgoulias
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

5.  Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.

Authors:  A Ammar; Y Sahraoui; A Tsapis; A M Bertoli; C Jasmin; V Georgoulias
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

6.  Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity.

Authors:  Lokesh Agrawal; W Haq; Carl Veith Hanson; D Nageswara Rao
Journal:  J Immune Based Ther Vaccines       Date:  2003-11-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.